Clinical trials: Adrenocortical Tumor
Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be…
- Conditions
- Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
- Trial name
- NCT03370718
- Testing
- Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well gossypol acetic acid works in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery.
- Conditions
- Recurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
- Trial name
- NCT00848016
- Testing
- R-(-)-gossypol acetic acid
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Pituitary Adenoma
Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation.
- Trial name
- NCT02574793
- Testing
- continuous glucose monitoring
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Adrenocortical Carcinoma, Pheochromocytoma
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT07743138
- Testing
- Ivonescimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
- Trial name
- NCT07138274
- Testing
- Metyrapone 250 mg Oral Tablets
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Primary Aldosteronism, Adrenal Cushing Syndrome
Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death
Sudden Cardiac Death is a leading cause of mortality and remains a major public health burden worldwide. Cardiac arrest due to coronary heart disease explains a large proportion of the cases, but if autopsy is not performed the…
- Conditions
- Primary Aldosteronism, Adrenal Cushing Syndrome, Pheochromocytoma, Endocrine Neoplasia
- Trial name
- SuddenDeath (NCT05446779)
- Testing
- Adrenal aldosterone synthase (CYP11B2) staining, Adrenal cortisol synthase (CYP11B1) staining, Histopathological analysis
- Where
- Finland
- Volunteers
- 400 people
- Sponsor
- Helsinki University Central Hospital
Cushing's Syndrome
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This is an observational study to confirm the presence of recurrent or persistent endogenous Cushing's syndrome in patients who have had primary surgical and/or radiation therapy for Cushing's disease and continue to manifest…
- Trial name
- NCT00796783
- Testing
- Cushing's syndrome confirmation
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Adrenocortical Carcinoma
Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood.
- Trial name
- AVS for ACC (NCT05660889)
- Testing
- Blood sampling.
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Erasmus Medical Center
Carcinoma, Adrenal Cortical
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical…
- Trial name
- NCT00094497
- Testing
- Etoposide, Doxorubicin, Cisplatin
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 304 people
- Sponsor
- Collaborative Group for Adrenocortical Carcinoma Treatment
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Cushing Syndrome, Pheochromocytoma
Metabolic Myopathy in Endocrinopathy
Endocrine diseases including Cushing's syndrome and phaeochromocytoma/paraganglioma (PPGL) but not Conn's syndrome are associated with muscle wasting and weakness.
- Conditions
- Cushing Syndrome, Pheochromocytoma, Conns Syndrome, Metabolic Myopathy
- Trial name
- LYDIA (NCT05456997)
- Testing
- Muscle biopsy
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Barts & The London NHS Trust
Adrenocortical Carcinoma
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma
Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the…
- Trial name
- NCT02015026
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare tumor with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 months.
- Trial name
- NCT03127774
- Testing
- Cisplatin, Sodium thiosulfate, Cytoreductive surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Primary Aldosteronism, Aldosterone-Producing Adenoma
Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism
In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous…
- Conditions
- Primary Aldosteronism, Aldosterone-Producing Adenoma, Hypercortisolism
- Trial name
- NCT05368090
- Testing
- EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation, EUS-RFA of left adrenal tumour in PA, "debulking group", EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Haukeland University Hospital
Adrenal Tumor, Adrenocortical Carcinoma
Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors. Since those tumors can belong to a variety of entities the therapeutic consequences also show considerable…
- Trial name
- NCT00454103
- Testing
- 123I-Iodometomidate
- Where
- Germany
- Sponsor
- University of Wuerzburg
Autonomous Cortisol Secretion, Mild Autonomous Cortisol Secretion (MACS)
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).
- Trial name
- NCT06106295
- Testing
- Metyrapone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Adrenocortical Carcinoma, Pheochromocytoma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
- Conditions
- Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
- Trial name
- Spencer (NCT04187404)
- Testing
- EO2401, Nivolumab
- Where
- 12 sites in United States, Denmark and 6 more
- Volunteers
- 70 people
- Sponsor
- Enterome